Amgen’s three medicines
Dr. Reddy’s Laboratories Ltd has expanded its strategic collaboration with Amgen to market and distribute the latter’s three medicines in India in the therapy areas of oncology and osteoporosis.
Dr. Reddy’s will commercialise XGEVA® (denosumab), Vectibix® (panitumumab) and Prolia® (denosumab) in India.
In 2015, Dr. Reddy’s announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen’s Kyprolis® (carfilzomib), BLINCYTO® (blinatumomab) and Repatha™ (evolocumab) in India.
The collaboration leverages the capabilities of both companies, combining Amgen’s innovative therapies with Dr. Reddy’s deep understanding of patient and physician needs in India.
Penny Wan, Amgen Vice President and General Manager, Japan Asia Pacific Region, said, ”Amgen is committed to addressing unmet medical needs of patients in India, and we are pleased with the commitment Dr. Reddy’s has demonstrated toward making our medicines available in India as quickly as possible.”
XGEVA is a RANK ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone.
Vectibix is an epidermal growth factor receptor (EGFR) antagonist approved in India for the treatment of adult patients with wild-type KRAS metastatic colorectal cancer (m-CRC) as first line treatment as monotherapy following disease progression, in wild type RAS m-CRC as first-line combination with FOLFOX and in second line in combination with FOLFIRI after prior treatment with fluoropyrimidine-based chemotherapy (excluding irinotecan).
Prolia is a RANK ligand (RANKL) inhibitor approved in India for treatment of post-menopausal women with osteoporosis at high risk for fracture and also for treatment of increased bone mass in men with osteoporosis. fii-news.com
